Screening for prostate cancer remains controversial
The introduction of prostate specific antigen (PSA) testing as a screening tool has transformed the clinical landscape of prostate cancer. Screening allows prostate cancer to be diagnosed many years earlier, offering hope that a newly detected cancer is still localised to the prostate when treatment is curative. However, screening has also led to considerable false positive results and extensive overdiagnosis of disease that would not otherwise emerge clinically. We summarise current screening guidelines and review the evidence of benefit and harm of PSA testing.
The US Food and Drug Administration approved PSA testing to monitor progression of cancer among men with prostate cancer in 1986 and for early detection of prostate cancer in 1994. Nevertheless, many agencies in the US and Europe do not recommend routine prostate cancer screening (box 1). The European Association of Urology, for instance, states that "Current published data are insufficient to recommend the adoption of . . . [
Starke, JR., Mucci, L., Rothman, K., & Adami, HO. (2009). Screening for prostate cancer remains controversial. BMJ (Clinical research ed.), 339(7724), b3601. https://doi.org/10.1136/bmj.b3601